A Prosperity Partnership for the Design of Next-Generation Antibody Drug Bioconjugates (Next-Gen ADC)

下一代抗体药物生物共轭物（下一代 ADC）设计的繁荣合作伙伴关系

• 批准号: BB/Y003268/1
• 负责人: Glenn Burley
• 金额: $ 362.81万
• 依托单位: University of Strathclyde
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FY003268%2F1
• 关键词: Prosperity; Partnership; Design; Next; Generation

GlaxoSmithKline (GSK) is a leading global healthcare company that discovers, develops and manufactures medicines for respiratory disorders, cancer, heart disease, and skin conditions like psoriasis. GSK manufactures over 4 billion packs of medicines each year, with the goal of addressing society's healthcare grand challenges. GSK continually seeks to improve the efficiency, efficacy and sustainability of new medicines. One area of interest to GSK is the expansion of their antibody drug conjugate (ADC) portfolio. Antibody-drug conjugates are hybrid medicines based on attaching antibodies to small molecule drugs, which improves the targeting of the medicine. ADCs combine the ability to deliver medicines to diseased cells and tissues a drug payload of interest. The advantage of ADCs over conventional medicines is they have the potential to reduce side effects associated with a drug by only delivering the it to the diseased parts of the body. This Prosperity Partnership aims to build on an existing vibrant collaboration between GSK and the University of Strathclyde (UoS). The strengths of each partner will be leveraged to deliver a range of new methods and approaches to address some of the major challenges in the discovery, development, and application of ADCs and a broader array of bioconjugates. Our vision is to increase the efficiency of discovering and turning ADCs into future medicines in terms of the time and energy it takes to make new medicines. Our approaches and research will mean that transformative new ADCs will be made at lower costs, with a greater speed of production, and turn into new medicines at a much faster pace.The two key challenge areas covered in our partnership include: 1. The curation and standardisation of data acquisition across the entire landscape of experimental analysis of an ADC. The use of data in designing ADCs is usually protected by individual companies and are not accessible to researchers. We will develop a standardised data analytical platform that forms the basis for an artificial intelligence informed decision-making process towards the end of the partnership. This will help the broader pharmaceutical industry and academics to successfully design new medicines based on ADCs.2. Making Next generation ADCs. The discovery and development of new ADCs require efficient and flexible chemical reactions to link drugs to antibodies. We will develop a toolbox of new reagents to facilitate the more expedient and streamlined preparation of ADCs. Through integrating the individual scientific themes of the projects, and the expertise from both GSK and the University of Strathclyde, we will make a major contribution to the wider pharmaceutical and biotechnology sectors. We will also train and develop the next generation of the drug discovery workforce that will develop future medicines based on ADCs. Finally, a key outcome of this partnership will be to assist GSK in achieving its mission of discovering and developing transformative medicines faster to help people do more, feel better, and live longer.

葛兰素史克（GSK）是全球领先的医疗保健公司，致力于发现、开发和生产治疗呼吸系统疾病、癌症、心脏病和牛皮癣等皮肤病的药物。GSK每年生产超过40亿包药品，以解决社会医疗保健方面的重大挑战为目标。GSK不断寻求提高新药的效率、疗效和可持续性。GSK感兴趣的一个领域是扩大其抗体药物偶联物（ADC）组合。抗体-药物偶联物是基于将抗体附着在小分子药物上的混合药物，它提高了药物的靶向性。adc结合了将药物输送到患病细胞和组织的能力和感兴趣的药物有效载荷。adc相对于传统药物的优势在于，它们有可能通过只将药物输送到身体患病部位来减少与药物相关的副作用。这一繁荣伙伴关系旨在建立在GSK和斯特拉斯克莱德大学（UoS）之间现有的充满活力的合作基础上。双方将利用各自的优势，提供一系列新的方法和途径，以解决adc和更广泛的生物偶联物的发现、开发和应用中的一些主要挑战。我们的愿景是在制造新药所需的时间和精力方面提高发现adc并将其转化为未来药物的效率。我们的方法和研究将意味着变革性的新型adc将以更低的成本、更快的生产速度生产，并以更快的速度转化为新药。我们的伙伴关系涉及的两个主要挑战领域包括：1。数据采集的管理和标准化横跨整个景观的ADC的实验分析。在设计adc时使用的数据通常由个别公司保护，研究人员无法访问。我们将开发一个标准化的数据分析平台，为合作结束时的人工智能知情决策过程奠定基础。这将有助于更广泛的制药行业和学术界成功地设计基于adc的新药。制造下一代adc。新的adc的发现和开发需要有效和灵活的化学反应将药物与抗体连接起来。我们将开发一个新试剂工具箱，以方便更方便和简化adc的制备。通过整合项目的各个科学主题，以及葛兰素史克和斯特拉斯克莱德大学的专业知识，我们将为更广泛的制药和生物技术领域做出重大贡献。我们还将培训和发展下一代药物发现工作人员，他们将开发基于adc的未来药物。最后，此次合作的一个关键成果将是帮助GSK实现其使命，即更快地发现和开发变革性药物，帮助人们做得更多、感觉更好、活得更久。